LME 636

Drug Profile

LME 636

Alternative Names: ESBA 1622; LME636

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ESBATech
  • Developer Alcon
  • Class Anti-inflammatories; Antibodies; Eye disorder therapies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes; Uveitis

Most Recent Events

  • 11 Sep 2017 Phase-II development is ongoing in USA (Apexigen pipeline, September 2017)
  • 01 Mar 2016 Alcon Research completes a phase II trial in Uveitis in USA (Ophthalmic) (NCT02482129)
  • 01 Oct 2015 Alcon Research completes a phase II trial in Dry eyes in USA (NCT02365519)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top